TransCode Therapeutics, Inc. (NASDAQ:RNAZ) Short Interest Update

TransCode Therapeutics, Inc. (NASDAQ:RNAZ) was the target of a large decrease in short interest in June. As of June 15th, there was short interest totalling 448,500 shares, a decrease of 56.0% from the May 31st total of 1,020,000 shares. Based on an average daily volume of 1,260,000 shares, the days-to-cover ratio is presently 0.4 days. Approximately 6.9% of the shares of the stock are sold short.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in TransCode Therapeutics stock. Virtu Financial LLC acquired a new position in TransCode Therapeutics, Inc. (NASDAQ:RNAZ) during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 55,329 shares of the company’s stock, valued at approximately $37,000. Virtu Financial LLC owned about 0.84% of TransCode Therapeutics as of its most recent SEC filing.

Analyst Upgrades and Downgrades

Separately, HC Wainwright restated a “buy” rating and issued a $3.00 target price on shares of TransCode Therapeutics in a research report on Wednesday, May 29th.

TransCode Therapeutics Trading Down 0.5 %

RNAZ stock traded down $0.01 during midday trading on Friday, reaching $1.01. 217,592 shares of the stock were exchanged, compared to its average volume of 381,726. TransCode Therapeutics has a 52 week low of $0.42 and a 52 week high of $128.00. The company has a fifty day moving average price of $1.09 and a 200 day moving average price of $1.80.

About TransCode Therapeutics

TransCode Therapeutics, Inc, a ribonucleic acid (RNA) oncology company, focuses on the development and commercialization of drugs and diagnostics for treating and identifying various cancers. Its lead therapeutic candidate is TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in a range of cancers, including breast, pancreatic, ovarian, colon cancer, glioblastomas, and others.